Therapeutic use of a growth factor, METRNL

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10034918
SERIAL NO

15589323

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HOBA THERAPEUTICS APSOLE MAALOES VEJ 3 COPENHAGEN 2200

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andrade, Nuno Miguel Gomes Vienna, AT 4 22
Fjord-Larsen, Lone Rødovre, DK 4 22
Johansen, Teit E Hørsholm, DK 26 190
Jorgensen, Jesper R Frederiksberg, DK 3 3
Wahlberg, Lars Ulrik Tiverton, US 20 71

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 31, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 31, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00